This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC

Phase 1

• Conditions: Metastatic Renal Cell Carcinoma; MedDRA version: 27.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2018-004567-31-DE
• Lead Sponsor: Exelixis, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-20
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 840

Inclusion Criteria

- Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.
- Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.
- Measurable disease per RECIST 1.1 as determined by the Investigator.
- Karnofsky Performance Status (KPS) = 70%.
- Adequate organ and marrow function.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 546
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 294

Exclusion Criteria

- Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.
- Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary lesions, or lesion invading major pulmonary blood vessels.

-Other clinically significant disorders such as:
i. Autoimmune disease that has been symptomatic or required
treatment within the past two years from the date of randomization
ii. Any condition requiring systemic treatment with either
corticosteroids (> 10 mg daily prednisone equivalent) or other
immunosuppressive medications within 14 days of randomization.
iii. Active infection requiring systemic treatment. Acute or chronic
hepatitis B or C infection, known human immunodeficiency virus (HIV)
or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive
test for tuberculosis infection where there is clinical or radiographic
evidence of active mycobacterial infection.
iv. Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization
-Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain
metastasis) within 4 weeks prior to randomization. Minor surgeries
within 10 days prior to randomization. Subjects must have complete
wound healing from majo or minor surgery before randomization.
- Any other active malignancy at time of randomization or diagnosis of
another malignancy within 3 years prior to randomization that requires
active treatment, except for locally curable cancers that have been
apparently cured, such as basal or squamous cell skin cancer, superficial
bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The objective of this study is to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC. ;Secondary Objective: Not applicable;Primary end point(s): Duration of PFS (Progression-Free Survival), per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)<br>;Timepoint(s) of evaluation of this end point: The first tumor assessment after randomization should be performed at W10D1 (± 7 days). Subsequent tumor assessments should be performed every 8 weeks (± 7 days) from randomization through Week 50. Upon completion of 50 weeks on study, these assessments will be performed every 12 weeks (± 7 days). Additional imaging of potential disease sites should be performed whenever radiographic PD is suspected.

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Duration of OS (overall survival);Timepoint(s) of evaluation of this end point: Overall survival (OS) will continue to be assessed every 12 weeks (± 14 days) after the second post-treatment follow-up visit (FU-2), which occurs 100 (±14) days after discontinuation of study treatment. Subjects will be followed until death or Sponsor decision to no longer collect these data